TNF and arthropathy: Starting at 8 years of age, F2:II-4 experienced the onset of a non-destructive, deforming arthropathy which has been refractory to broad-spectrum immunosuppression, anti-IL-1 receptor, anti-IL-1β and anti-TNFα therapies (Fig. 1e).